Cyclohexene → HCID 178418962, Verbindung

HRID 1072635Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1072635
[C:1]([NH:4][CH:5]([CH2:51][C:52]1[CH:57]=[CH:56][C:55]([OH:58])=[CH:54][CH:53]=1)[C:6]([NH:8][CH:9]([CH2:43][C:44]1[CH:49]=[CH:48][C:47]([F:50])=[CH:46][CH:45]=1)[C:10]([N:12]1[CH2:17][CH:16]([CH2:18][C:19]2[CH:28]=[CH:27][C:26]3[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=3)[CH:20]=2)[NH:15][C:14](=[O:29])[CH:13]1[CH2:30][C:31]1[N:32]=[CH:33][N:34](CC2C=CC=CC=2)[CH:35]=1)=[O:11])=[O:7])(=[O:3])[CH3:2].C1CCCCC=1>C(O)C.C(O)(=O)C.[Pd]>[C:1]([NH:4][CH:5]([CH2:51][C:52]1[CH:57]=[CH:56][C:55]([OH:58])=[CH:54][CH:53]=1)[C:6]([NH:8][CH:9]([CH2:43][C:44]1[CH:45]=[CH:46][C:47]([F:50])=[CH:48][CH:49]=1)[C:10]([N:12]1[CH2:17][CH:16]([CH2:18][C:19]2[CH:28]=[CH:27][C:26]3[C:21](=[CH:22][CH:23]=[CH:24][CH:25]=3)[CH:20]=2)[NH:15][C:14](=[O:29])[CH:13]1[CH2:30][C:31]1[N:32]=[CH:33][NH:34][CH:35]=1)=[O:11])=[O:7])(=[O:3])[CH3:2]

Komponenten

5

Edukt 2

HCID 8079Cyclohexene2×HCID 696527502-acetylamino-N-[2-[2-(1-benzyl-1H-imidazol-4-ylmethyl)-5-naphthalen-2-ylmethyl-3-oxo-piperazin-1-yl]-1-(4-fluorobenzyl)-2-oxo-ethyl]-3-(4-hydroxyphenyl)-propionamide

Produkt 1

HCID 178418962HCID 178418962, Verbindung

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 23938PalladiumKatalysatorHCID 18476134Acetic acid ethanolLösungsmittel

Versuchsvorschrift

2-acetylamino-N-[2-[2-(1-benzyl -1H-imidazol-4-ylmethyl)-5-naphthalen-2-ylmehtyl-3-oxo-piperazin-1-yl]-1-(4-fluorobenzyl)-2-oxo-ethyl]-3-(4-hydroxyphenyl)-propionamide, 73, (0.22 g, 0.28 mmol) is dissolved in ethanol/acetic acid (4:1) (3 mL). Cyclohexene (3 mL) and Pd-black are added and the solution is refluxed with periodic replenishment of cyclohexene. The reaction is monitored by TLC and after 2 days is cooled and filtered through Celite to remove the catalyst. The filtrate is concentrated in vacuo to afford an oil which is purified by reverse phase C18 prep HPLC to afford the desired product.

Aufarbeitung

  1. temperatureis cooled
  2. filtrationfiltered through Celite
  3. customto remove the catalyst
  4. concentrationThe filtrate is concentrated in vacuo
  5. customto afford an oil which
  6. customis purified by reverse phase C18 prep HPLC

Quellen und Nachweise

ORD-Eintrag
ord-532e90c5df73486aa3183da0c661bf5d
Quelldatensatz
uspto-grants-2005_06
Patentnummer
US06911447B2

Notizen zur Reaktion

Wird geladen…